References

1. Christopher Murray,Alan Lopez (1997). Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study.
2. S Yusuf,S Reddy,S Ounpuu,S Anand (2001). Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transitions, risk factors and impact of urbanization.
3. E Topol,R Califf,M Vandormael,C Grines,B George,M Sanz,T Wall,M O'brien,M Schwaiger,F Aguirre (1992). A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group..
4. G Baxter,Z Ebrahim (2002). Role of bradykinin in preconditioning and protection of the ischaemic myocardium.
5. Stefan Ryter,Jawed Alam,Augustine Choi (2006). Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications.
6. C Murry,R Jennings,K Reimer (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
7. F Tomai,F Crea,L Chiariello,P Gioffrè (1999). Ischemic Preconditioning in Humans: Models, Mediators, and Clinical Relevance.
8. M Cohen,G Liu,J Downey (1991). Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits.
9. C Baines,M Cohen,J Downey (1999). Signal Transduction in Ischemic Preconditioning: The Role of Kinases and Mitochondrial KATP Channels.
10. Elizabeth Murphy (2004). Primary and Secondary Signaling Pathways in Early Preconditioning That Converge on the Mitochondria to Produce Cardioprotection.
11. David Stokoe,Leonard Stephens,Terry Copeland,Piers Gaffney,Colin Reese,Gavin Painter,Andrew Holmes,Frank Mccormick,Phillip Hawkins (1997). Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B.
12. P Ferdinandy,R Schulz,G Baxter (2007). Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning and Postconditioning.
13. Mgm Prendes,M Gonzalez,E Savino,A Varela (2007). Role of endogenous nitric oxide in classic preconditioning in rat hearts.
14. C Csonka,E Varga,P Kovas,P Ferdinandy,I Blasig,Z Szilvassy (1999). Heme oxygenase and cardiac function in ischemic/reperfused rat hearts.
15. S Penumathsa,M Thirunavukkarasu,L Zhan,G Maulik,V Menon,D Bagchi (2008). Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/AKT/eNOS signaling pathway in diabetic myocardium.
16. Del Valle,H Lascano,E Negroni,J (2002). Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels.
17. A Tsang,D Hausenloy,M Mocanu,R Carr,D Yellon (2005). Preconditioning the diabetic heart: the importance of Akt phosphorylation.
18. A Wynne,D Hausenloy,M Mocanu,D Yellon (2007). Glimepiride reduces the threshold for ischemic preconditioning in the diabetic heart.
19. Eric Gross,Anna Hsu,Garrett Gross (2007). Diabetes Abolishes Morphine-Induced Cardioprotection via Multiple Pathways Upstream of Glycogen Synthase Kinase-3β.
20. H Yadav,M Singh,P Sharma (2010). Involvement of GSK-3β in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heart.
21. H Patel,F Murray,P Insel (2007). Caveolae as organizers of pharmacologically relevant signal transduction molecules.
22. R Ostrom,P Insel (2004). The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology.
23. O Feron,J Balligand (2006). Caveolin and the regulation of endothelial nitric oxide synthase in the heart.
24. Srikanth Koneru,Suresh Penumathsa,Mahesh Thirunavukkarasu,Samson Samuel,Lijun Zhan,Zhihua Han,Gautam Maulik,Dipak Das,Nilanjana Maulik (2007). Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with eNOS and GLUT-4.
25. M Bucci,F Roviezzo,V Brancaleone,M Lin,A Lorenzo,C Cicala (2004). Diabetic mouse angiopathy is linked to progressive sympathetic receptor deletion coupled to an enhanced caveolin-1 expression.
26. Stefan Ryter,Jawed Alam,Augustine Choi (2006). Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications.
27. H Kim,X Wang,F Galbiati,S Ryter,A Choi (2004). Caveolae compartmentalization of heme oxygenase-1 in endothelial cells.
28. X Liu,J Wei,D Peng,M Layne,S Yet (2005). Absence of Heme Oxygenase-1 Exacerbates Myocardial Ischemia/Reperfusion Injury in Diabetic Mice.
29. O Woodman,M Missen,M Boujaoude (2004). Daidzein and 17 beta-estradiol enhance nitric oxide synthase activity associated with an increase in calmodulin and a decrease in caveolin-1.
30. Tetsuya Yoshida,Nilanjana Maulik,Ye-Shih Ho,Jawed Alam,Dipak Das (2001). H _mox-1 Constitutes an Adaptive Response to Effect Antioxidant Cardioprotection.
31. Csaba Csonka,Edit Varga,Peter Kovacs,Peter Ferdinandy,Ingolf Blasig,Zoltan Szilvassy,Arpad Tosaki (1999). Heme oxygenase and cardiac function in ischemic/reperfused rat hearts.
32. M Li,S Peterson,D Husney,M Inaba,K Guo,A Kappas (2007). Long-lasting expression of HO-1 delays progression of type I diabetes in NOD mice.
33. E Masini,A Vannacci,C Marzocca,S Pierpaoli,L Giannini,O Fantappie (2003). Hemeoxygenase-1 and the ischemia-reperfusion injury in the rat heart.
34. Vinay Parikh,Manjeet Singh (1999). Possible role of cardiac mast cell degranulation and preservation of nitric oxide release in isolated rat heart subjected to ischaemic preconditioning.
35. Kanwaljit Chopra,Manjeet Singh,Nalini Kaul,Khurshidi. Andrabi,N Ganguly (1992). Decrease of myocardial infarct size with desferrioxamine: possible role of oxygen free radicals in its ameliorative effect.
36. Stephen Peterson,Daniel Husney,Adam Kruger,Rafal Olszanecki,Francesca Ricci,Luigi Rodella,Alessandra Stacchiotti,Rita Rezzani,John Mcclung,Wilbert Aronow,Susumu Ikehara,Nader Abraham (2007). Long-Term Treatment with the Apolipoprotein A1 Mimetic Peptide Increases Antioxidants and Vascular Repair in Type I Diabetic Rats.
37. P Ajmani,H Yadav,M Singh,P Sharma (2011). Possible involvement of caveolin in attenuation of cardioprotective effect of ischemic preconditioning in diabetic rat heart.
38. John Baker,Jidong Su,Xiangping Fu,Anna Hsu,Garrett Gross,James Tweddell,Neil Hogg (2007). Nitrite confers protection against myocardial infarction: Role of xanthine oxidoreductase, NADPH oxidase and KATP channels.
39. T Williams,M Lisanti (2004). The caveolin genes: from cell biology to medicine.
40. J Couet,M Sargiacomo,M Lisanti (1997). Identification of peptide and protein ligands for the caveolinscaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins.
41. H Bohlen,Geoffrey Nase (2001). Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced βII PKC activation.
42. Owen Woodman,Melinda Missen,Mirna Boujaoude (2004). Daidzein and 17β-Estradiol Enhance Nitric Oxide Synthase Activity Associated with an Increase in Calmodulin and a Decrease in Caveolin-1.
43. S Penumathsa,S Koneru,S Samuel,L Zhan,V Menon,N Maulik (2008). Red wine polyphenol resveratrol regulates Heme Oxygenase-1 conversely for the disruption of Caveolin-1/eNOS platform and improve left ventricular function in Ischemic Hypercholesterolemic Myocardium.